Sano T,Sasako M,Yamamoto S, et al.Gastric cancer surgery:morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501[J]. J Clin Oncol,2004,22:2767-2773.
[2]
Kuniaki C,Shimada H,Yamaoka H,Wakasugi J,Takahashi M,Akiyama H, etal.Significance of para-aortic lymph node dissection for advancedgastric cancer[J].Hepatogastroenterology, 1999,46:2635-2642.
Maeta M,Yamashiro H,Saito H, et al.A prospective pilot study of extened (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy[J].Surgery,1999,125(3):325-331.
[6]
Koizumi W, Akiya T, Sato A, et al. Phase Ⅱ study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study [J]. Cancer chemother pharmacol,2010,65(6):1093-1099.
[7]
Boku N.Chemotherapy for metastatic disease:review from JCOG trial[J].International Journal of Clinical Oncology,2008,13(3):196.
2016, Vol. 27 
